Research Article
Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
Figure 4
Mucosa TNC mRNA levels are associated with response to infliximab therapy in UC patients. (a) mRNA levels of TNC in control, responsive (R), and nonresponsive (NR) group; (b) rates of responsive or nonresponsive to infliximab in patients with low or high TNC expression; (c) receiver operating characteristic (ROC) curves illustrating the specificity and sensitivity in mucosa TNC levels to differentiate infliximab responsive or nonresponsive for UC. and .
(a) |
(b) |
(c) |